Ciron Drugs AND Pharmaceuticals Private Limited

Ciron Drugs and Pharmaceuticals Private Limited, established on June 4, 1990, is a privately held pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Its Corporate Identification Number (CIN) is U24246MH1990PTC056735.

The authorized share capital of Ciron Drugs is ₹10 million, with a paid-up capital of ₹8.3 million. The company operates under the ownership of its directors, including Keyur Ratanshi Shah, Kirti Talakshi Shah, Samir Ratanshi Shah, Dhaval Kirti Shah, and Keyur Ratanshi Shah. Ciron Drugs maintains an active status and is registered with the Registrar of Companies in Mumbai.

Ciron Drugs operates two fully automated manufacturing plants located in Tarapur and Palghar, Maharashtra. These facilities are equipped with cutting-edge machinery and adhere to stringent quality control measures to ensure the production of high-quality pharmaceutical formulations. The plants are certified for Good Manufacturing Practice (GMP) standards, including WHO GMP and cGMP norms as per the Revised Schedule M by the Drug Controller General of India.

The leadership team at Ciron Drugs is headed by Managing Director Keyur Ratanshi Shah, who has been with the company since its inception. Other key executives include Kirti Talakshi Shah, Samir Ratanshi Shah, Dhaval Kirti Shah, and Keyur Ratanshi Shah, all of whom hold directorial positions. Their combined experience and strategic direction have been instrumental in the company's growth and expansion in the pharmaceutical industry.

Ciron Drugs has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained necessary regulatory approvals and market access in these regions, ensuring compliance with international standards for pharmaceutical products. This expansion reflects Ciron Drugs' commitment to delivering high-quality pharmaceutical formulations to a global clientele.

Ciron Drugs has strategically penetrated emerging markets in Africa, Latin America, and Southeast Asia. The company's products are prequalified by the World Health Organization (WHO), facilitating access to these regions and enhancing its global footprint. This approach underscores Ciron Drugs' dedication to improving healthcare accessibility in developing markets through the provision of quality pharmaceutical products.

Ciron Drugs demonstrates a diversified geographic strategy by expanding its presence across both developed and emerging markets. This diversification mitigates concentration risk and positions the company to leverage growth opportunities worldwide. The strategic direction focuses on balancing market penetration to achieve sustainable growth and resilience in the global pharmaceutical sector.

Ciron Drugs' manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA), indicating compliance with FDA standards for pharmaceutical manufacturing. The company has filed Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs) with the FDA, facilitating the approval of its generic pharmaceutical products in the U.S. market. Inspection histories reflect adherence to FDA regulations, ensuring the safety and efficacy of its products.

Ciron Drugs' manufacturing facilities are certified for compliance with WHO Good Manufacturing Practice (GMP) standards, ensuring the production of high-quality pharmaceutical products. Additionally, the company holds EU GMP certificates, affirming its adherence to European Union standards for pharmaceutical manufacturing. These certifications underscore Ciron Drugs' commitment to maintaining excellence in manufacturing practices.

Ciron Drugs holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company has obtained approvals from state drug controllers and export No Objection Certificates (NOCs), facilitating the export of its pharmaceutical products. These regulatory compliances ensure that Ciron Drugs' products meet the required standards for safety, efficacy, and quality in both domestic and international markets.

As of March 2026, Ciron Drugs has maintained a clean regulatory record, with no reported Form 483 observations, warning letters, or import alerts from regulatory bodies such as the FDA. This indicates the company's consistent adherence to regulatory standards and its commitment to maintaining high-quality manufacturing practices.

Ciron Drugs operates in a competitive landscape with several key players in the pharmaceutical manufacturing sector. While specific competitors are not identified in the available data, Ciron Drugs distinguishes itself through its diversified product portfolio, including corticosteroids, antifungals, and antibiotics, which collectively constitute a significant portion of its exports. The company's strategic focus on both developed and emerging markets further enhances its competitive positioning.

Ciron Drugs' key differentiators include its comprehensive product portfolio, adherence to international manufacturing standards, and strategic market diversification. The company's commitment to quality is evidenced by its WHO GMP and EU GMP certifications. Additionally, Ciron Drugs' focus on emerging markets, facilitated by WHO prequalification, enables it to address diverse healthcare needs globally.

Ciron Drugs' current strategic direction emphasizes the production of generic pharmaceutical formulations, with a focus on expanding its presence in both developed and emerging markets. The company's future outlook includes exploring opportunities in specialty pharmaceuticals and contract development and manufacturing (CDMO) services, aiming to enhance its market share and operational capabilities.

Ciron Drugs has demonstrated a strong track record in pharmaceutical manufacturing, with consistent export volumes and adherence to international quality standards. The company's reliability is indicated by its clean regulatory history and certifications from recognized authorities. These factors position Ciron Drugs as a dependable supplier in the global pharmaceutical market.

Importers should verify the following certifications when considering Ciron Drugs as a supplier:

• FDA Facility Registration: Confirm the registration status of Ciron Drugs' manufacturing facilities with the U.S. FDA.

• WHO GMP Certification: Ensure the manufacturing facilities are certified for compliance with WHO Good Manufacturing Practice standards.

• EU GMP Certification: Verify the EU GMP certification of the manufacturing facilities.

• ISO 9001:2008 Certification: Check for ISO 9001:2008 certification, indicating a quality management system compliant with international standards.

These certifications can typically be verified through official regulatory bodies or directly from the company's official communications.

When conducting due diligence on Ciron Drugs, consider the following steps:

• Verify Regulatory Certifications: Confirm the validity of FDA, WHO GMP, EU GMP, and ISO 9001:2008 certifications.

• Review Financial Statements: Examine the company's financial records for the latest fiscal year to assess financial health.

• Assess Manufacturing Facilities: Evaluate the compliance of manufacturing facilities with international standards and inspect for any recent regulatory inspections or audits.

• Check Export Records: Review export volumes and consistency to gauge reliability and market demand.

• Evaluate Product Portfolio: Analyze the diversity and quality of the product portfolio to ensure alignment with market needs.

Be vigilant for any discrepancies in certifications, financial irregularities, or negative regulatory histories that may indicate potential risks.